Cat#:RP-1294H;Product Name:Recombinant Human RANKL / OPGL / TNFSF11 / CD254 Protein;Synonym:CD254,hRANKL2,ODF,OPGL,OPTB2,RANKL,sOdf,TRANCE,TNF superfamily member 11,TNFSF11;Background:This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found. [provided by RefSeq, Jul 2008];Description:A DNA sequence encoding the human TNFSF11/RANKL protein (O14788-2) (Gly 63-Asp 244) was expressed. Recombinant human RANKL protein was produced in Human cells. The RANKL human recombinant protein was purified by our unique chromatographic techniques.;Source:Human Cells;Predicted N Terminal:Gly63;Molecular Characterization:The recombinant human TNFSF11 protein consists of 182 amino acids and has a calculated molecular mass of 20.5 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of the protein is approximately 27 kDa due to the glycosylation.;Purity:Greater than 95% as determined by SDS-PAGE;Endotoxin:< 1.0 EU per ug of the recombinant human TNFSF11 protein as determined by the LAL method;Bioactivity:The bioactivity of recombinant human RANKL protein was determined by measuring the ability of human RANKL to induce TRAP activity in Raw 264.7 cells. The ED50 for this effect is typically 1.5-7.5 ng/mL.;Formulation:Recombinant human TNFSF11 protein was lyophilized from sterile PBS, pH 7.4;Stability:Recombinant human RANKL Proteins are stable for up to 1 year from date of receipt at -70℃;Reconstitution:Please see related COA for specific instructions.;Storage:Lyophilized recombinant human RANKL protein is stable at 4-8℃ for 2-4 weeks. Upon reconstitution, Recombinant human RANKL protein should be stored at 4°C between 2-7 days and for future use below -20°C. Avoid freeze-thaw cycles.;References:1. Leibbrandt A, et al. (2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 1143: 123-50. 2.Schwarz EM, et al. (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther. 9 Suppl 1: S7. ;